Table 1.
Manifestations of the ovarian plasmacytoma reported in the present study
| Parameter | Value/Characteristic | |
|---|---|---|
| Info | Age/sex | 54, female |
| Site | L, ovary | |
| Symptoms | Mass, 4 cm, no pain | |
| US | L, uterine wall | Well-defined, hypoechoic nodule, 0.9×0.7 cm |
| L, adnexa | Well-defined, cystic mass with fine echoes, 4.9×4.2 cm | |
| Neutrophils (%) | 77 | |
| PET-CT | N/I | |
| CT | L, pel | oval, well-defined, homo, iso mass, 4.5×4.0 cm |
| MRI | pel | Roundish, well-defined, homo mass, 4.6×4.1×3.7 cm, hemo enhancement after CM |
| T1W1: isointense signals | ||
| T2W1: isointense signals | ||
| DWI: hyperintense signals | ||
| L, adnexa | ADC (mm2/s): 0.72×10-3 | |
| Visualization | L. ovary | 5×5 cm, mass, smooth, intact capsule |
| Histology | Tissue | Diffuse and loose |
| Cell | Eccentric nuclei, basophilic cytoplasm, spoke-wheel pattern | |
| IHC | + | CD138, L, MuM1, CD79a, CD38, Ki-67, Lambda |
| - | CD163, R, CK, CD19, CD20, CD56, CD117, α-inhibin, SF1, Kappa | |
| Plasma cell (%) | normal | 1.1% |
| abnormal | <0.01% | |
| FISH | + | Iq21 |
| - | RB1, IGH, P53, D13S319 | |
| Treatment | PCD-ID | |
| Follow-up | Stable within 2 yr | |
Note: Info: information; US: ultrasound; L: left; N/I: no other organ involvement; CT: Contrast-enhanced computed tomography; abd: abdomen; pel: pelvic cavity; homo: homologous; iso: isodense; CM: contrast medium; T1WI: T1-weighted imaging; T2WI: T2-weighted imaging; DWI: diffusion-weighted imaging; ADC: apparent diffusion coefficient; IHC: Immunohistochemistry; yr: years; FISH: fluorescence in situ hybridization; PCD: pomalidomide/cyclophosphamide/dexamethasone regimen; ID: ixazomib/dexamethasone.